• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Zura Bio Limited

    11/14/24 4:28:42 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ZURA alert in real time by email
    SC 13G/A 1 d11527943_13g-a.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

     

    Zura Bio Limited
    (Name of Issuer)

     

     

     

    Class A Ordinary Shares, $0.0001 par value
    (Title of Class of Securities)

     

     

     

    G9TY5A101
    (CUSIP Number)

     

     

     

    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [_] Rule 13d-1(b)

     

    [X] Rule 13d-1(c)

     

    [_] Rule 13d-1(d)

     

    __________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     
     

     

     

    CUSIP No. G9TY5A101    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Suvretta Capital Management, LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      4,860,939  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      4,860,939  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      4,860,939  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      7.6%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
     

    IA, OO

     

     

     
     
     

     

    CUSIP No. G9TY5A101  

     

    1. NAME OF REPORTING PERSONS
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
      Averill Master Fund, Ltd.
       
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
       
     

    (a) [_]

    (b) [_]

       
    3. SEC USE ONLY
       
       
       
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Cayman Islands
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
       
    5. SOLE VOTING POWER
       
      0
       
    6. SHARED VOTING POWER
       
      4,860,939
       
    7. SOLE DISPOSITIVE POWER
       
      0
       
    8. SHARED DISPOSITIVE POWER
       
      4,860,939
       
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
      4,860,939
       
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)                                                                                                     [_]
       
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
      7.6%
       
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      CO

     

     
     

     

     

     

    CUSIP No. G9TY5A101    
         
    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Aaron Cowen  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      U.S.A.  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      4,860,939  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      4,860,939  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      4,860,939  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      7.6%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
     

    IN, HC

     

     

     
             

     

     
     

     

     

    CUSIP No. G9TY5A101  

     

    Item 1. (a). Name of Issuer:
         
        Zura Bio Limited
         
      (b). Address of Issuer's Principal Executive Offices:
         
       

    42250 Executive Square, Suite 600

    La Jolla, California 92037

         

     

    Item 2. (a) – (c) Name, Principal Business Address, and Citizenship of Persons Filing:
         
       

    Suvretta Capital Management, LLC – Delaware

    Averill Master Fund, Ltd. – Cayman Islands

       

    Aaron Cowen – U.S.A.

     

         
       

    Suvretta Capital Management, LLC:

    540 Madison Avenue, 7th Floor

    New York, New York 10022

       

    United States of America

     

    Averill Master Fund, Ltd.:

    c/o Maples Corporate Services Limited

    P.O. Box 309

    Ugland House

    Grand Cayman KY1-1104

    Cayman Islands

     

    Aaron Cowen:

    c/o Suvretta Capital Management, LLC

    540 Madison Avenue, 7th Floor

    New York, New York 10022

         
      (d).   Title of Class of Securities:
         
        Class A Ordinary Shares, $0.0001 par value (the “Common Stock”)
         
      (e). CUSIP Number:
         
        G9TY5A101
         

     

    Item 3.   If This Statement is filed pursuant to ss.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a

     

      (a) [_] Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c).
           
      (b) [_] Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).
           
      (c) [_] Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).
           
      (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) [_] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
           
      (f) [_] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
           
      (g) [_] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
           
      (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
           
      (i) [_] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j)   [_] Group, in accordance with s.240.13d-1(b)(1)(ii)(J).

     

     
     

     

     

    Item 4. Ownership.
     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a)   Amount beneficially owned:
         
        Suvretta Capital Management, LLC – 4,860,939
        Averill Master Fund, Ltd. – 4,860,939
        Aaron Cowen – 4,860,939
         
      (b)   Percent of class:
         
        Suvretta Capital Management, LLC – 7.6%
        Averill Master Fund, Ltd. – 7.6%
        Aaron Cowen – 7.6%

     

     

       
      (c)   Number of shares as to which the person has:
         
        (i) Sole power to vote or to direct the vote  
             
          Suvretta Capital Management, LLC – 0
          Averill Master Fund, Ltd. – 0
          Aaron Cowen – 0
             
        (ii)   Shared power to vote or to direct the vote  
             
          Suvretta Capital Management, LLC – 4,860,939
          Averill Master Fund, Ltd. – 4,860,939
          Aaron Cowen – 4,860,939
             
        (iii) Sole power to dispose or to direct the disposition of  
             
          Suvretta Capital Management, LLC – 0
          Averill Master Fund, Ltd. – 0
          Aaron Cowen – 0
             
        (iv)   Shared power to dispose or to direct the disposition of  
             
          Suvretta Capital Management, LLC – 4,860,939
          Averill Master Fund, Ltd. – 4,860,939
          Aaron Cowen – 4,860,939

     

     
    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [_].
     
      N/A
       
       

     

     
     

     

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified.  A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
     
      N/A  
       
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary.  If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
     
      See Exhibit B attached hereto.
       
       
    Item 8. Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group.  If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
     
      N/A
       
       
    Item 9. Notice of Dissolution of Group.
     
    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity.  See Item 5.
     
      N/A
       
       
    Item 10. Certification.
     
      (b) The following certification shall be included if the statement is filed pursuant to §240.13d-1(c):
         
        By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      November 14, 2024
      (Date)
       
      Suvretta Capital Management, LLC*
       
      By:  /s/ Aaron Cowen
      (Signature)
       
      Authorized Signatory
     

    (Name/Title)

     

    Averill Master Fund, Ltd.*

       
      By:  /s/ Aaron Cowen
      (Signature)
       
      Director
      (Name/Title)
     

     

    Aaron Cowen*

     

      /s/ Aaron Cowen
      (Signature)
       
       

    *Each Reporting Person disclaims beneficial ownership over the securities reported herein except to the extent of its pecuniary interest therein.

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     

     

     
     

     

    Exhibit A

     

    AGREEMENT

     

    The undersigned agree that this Amendment 1 to Schedule 13G dated November 14, 2024 relating to the Class A Ordinary Shares, $0.0001 par value of Zura Bio Limited shall be filed on behalf of the undersigned.

      November 14, 2024
      (Date)
       
      Suvretta Capital Management, LLC
       
      By:  /s/ Aaron Cowen
      (Signature)
       
      Authorized Signatory
     

    (Name/Title)

     

    Averill Master Fund, Ltd.

       
      By:  /s/ Aaron Cowen
      (Signature)
       
      Director
      (Name/Title)
     

     

    Aaron Cowen

     

      /s/ Aaron Cowen
      (Signature)
       
       

     

     
     

     

    Exhibit B

     

    Aaron Cowen has beneficial ownership by virtue of his role as a control person of Suvretta Capital Management, LLC.

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Get the next $ZURA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZURA

    DatePrice TargetRatingAnalyst
    11/4/2024$15.00Outperform
    Leerink Partners
    9/5/2024$5.00Neutral
    H.C. Wainwright
    5/3/2024$26.00Overweight
    Piper Sandler
    10/10/2023$10.00Buy
    Ladenburg Thalmann
    8/25/2023$17.00Outperform
    Oppenheimer
    6/22/2023$20.00Buy
    Guggenheim
    6/14/2023$14.00Buy
    Chardan Capital Markets
    5/24/2023$20.00Strong Buy
    Raymond James
    More analyst ratings

    $ZURA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa

      TibuSHIELD has launched with the activation of its first clinical site This study is the first to evaluate dual inhibition of B-cell activating factor (BAFF) and interleukin-17A (IL-17A) pathways in adults with moderate to severe hidradenitis suppurativa (HS) TibuSHIELD will assess tibulizumab over a 28-week study period, comprising a 16-week primary efficacy assessment and a 12-week safety follow-up, conducted at clinical sites across the United States, Canada, and Europe, with an optional open-label extension (OLE) Topline results for the primary efficacy endpoint at Week 16, along with key secondary and exploratory outcomes, are anticipated in the third quarter of 2026 Zura Bio

      5/20/25 6:30:00 AM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates

      Advanced the Phase 2 TibuSURE clinical trial evaluating tibulizumab in adults with systemic sclerosis (SSc) Continued preparations for the planned Phase 2 trial evaluating tibulizumab in adults with hidradenitis suppurativa (HS), expected to initiate in Q2 2025 Strengthened the team with a strategic appointment to support clinical execution and organizational growth $170.6 million in cash and cash equivalents with cash runway anticipated through 2027 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio" or the "Company"), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases, today reported financial resul

      5/8/25 6:30:00 AM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates

      Achieved key milestones in 2024 that enhanced our leadership team, strengthened our financial position, and progressed our clinical pipeline Initiated the Phase 2 TibuSURE trial in adults with systemic sclerosis (SSc) Completed a $112.5 million private placement financing in April 2024, contributing to a total of $176.5 million in cash and cash equivalents, as of December 31, 2024 Cash runway anticipated through 2027, supporting operations and funding anticipated tibulizumab data readouts in SSc and hidradenitis suppurativa (HS) Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio" or the "Company"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for

      3/25/25 6:30:00 AM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ZURA
    Leadership Updates

    Live Leadership Updates

    See more
    • Zura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights

      Presented data for tibulizumab at EULAR 2024, highlighting the potential relevance of dual-inhibition of both IL-17A and BAFF in autoimmune and inflammatory diseases Expect to initiate Phase 2 studies evaluating tibulizumab for the treatment of systemic sclerosis (SSc) in 4Q 2024 and hidradenitis suppurativa (HS) in 2Q 2025 Strengthened management and advisory team with appointment of Robert Lisicki as CEO & formation of Scientific Advisory Board Cash, cash equivalents and investments of $188.4 million as of June 30, 2024, including $112.5 million from private placement executed in April 2024, anticipated to support operations as currently planned through 2027 Zura Bio Limited

      8/13/24 9:21:00 AM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer

      Significant 2023 milestones highlighted by successful Nasdaq listing, leadership team buildout, formation of strategic development and scientific plan On track to initiate Phase 2 study evaluating tibulizumab (ZB-106) for the treatment of systemic sclerosis (SSc) in 2H 2024 Appointment of CEO, Robert Lisicki, underscores Zura Bio's commitment to building leading immunology company as we prioritize excellence in strategic development and scientific planning Outgoing Founder and CEO, Someit Sidhu, M.D., will continue as a Board Director to leverage institutional knowledge and provide continued support Cash position as of December 31, 2023 totaling $99.8 million in cash, cash equi

      3/28/24 6:00:00 AM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Zura Bio Continues to Strengthen Leadership with Appointment of Robert Lisicki as President and Kiran Nistala as CMO

      Accomplished biopharmaceutical executives bring invaluable expertise and experience to Zura Bio's Clinical Development programs Executive Leadership hires position Zura Bio for Phase 2 clinical trial readiness across multiple indications in 2024 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced the appointments of Robert Lisicki as President and Chief Operating Officer, and Kiran Nistala, MBBS, PhD, as Executive Vice President Development and Chief Medical Officer, to the Executive Leadership Team. Mr. Lisicki will be responsible for developing an

      1/8/24 6:00:00 AM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ZURA
    Financials

    Live finance-specific insights

    See more
    • Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates

      Achieved key milestones in 2024 that enhanced our leadership team, strengthened our financial position, and progressed our clinical pipeline Initiated the Phase 2 TibuSURE trial in adults with systemic sclerosis (SSc) Completed a $112.5 million private placement financing in April 2024, contributing to a total of $176.5 million in cash and cash equivalents, as of December 31, 2024 Cash runway anticipated through 2027, supporting operations and funding anticipated tibulizumab data readouts in SSc and hidradenitis suppurativa (HS) Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio" or the "Company"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for

      3/25/25 6:30:00 AM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

      Expect to initiate Phase 2 studies evaluating tibulizumab for the treatment of systemic sclerosis (SSc) in Q4 2024 and hidradenitis suppurativa (HS) in Q2 2025 Cash, cash equivalents and investments totaling $188.2 million as of September 30, 2024, are anticipated to support operations, as currently planned, through 2027 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported financial results for the third quarter of 2024 and recent corporate updates. "In the third quarter of 2024, we made significant progress toward initiating our first Phase 2 tria

      11/7/24 6:30:00 AM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Zura Bio Reports Third Quarter 2023 Financial Results and Recent Business Highlights

      Initiating Phase 2 clinical trials in 2024 to evaluate ZB-106 (tibulizumab) in systemic sclerosis and hidradenitis suppurativa, and ZB-168 in alopecia areata Experienced team building the next Immunology leader Cash position of $103.9 million in cash, cash equivalents and investments is expected to support development and operations into 2026 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio") a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced its financial results for the quarter ended September 30, 2023, and recent business highlights. "In the third quarter, Zura Bio made significant progress

      11/13/23 6:30:00 AM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ZURA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Ploos Van Amstel Arnout bought $496,000 worth of Class A ordinary shares (80,000 units at $6.20), increasing direct ownership by 400% to 100,000 units (SEC Form 4)

      4 - Zura Bio Ltd (0001855644) (Issuer)

      5/23/24 8:53:36 AM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Howell Michael bought $24,999 worth of Class A ordinary shares (7,987 units at $3.13) (SEC Form 4)

      4 - Zura Bio Ltd (0001855644) (Issuer)

      4/24/24 6:54:25 PM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Nistala Kiran bought $10,000 worth of Class A ordinary shares (3,195 units at $3.13) (SEC Form 4)

      4 - Zura Bio Ltd (0001855644) (Issuer)

      4/24/24 6:53:25 PM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ZURA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $ZURA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $ZURA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $ZURA
    SEC Filings

    See more
    • Leerink Partners initiated coverage on Zura Bio Limited with a new price target

      Leerink Partners initiated coverage of Zura Bio Limited with a rating of Outperform and set a new price target of $15.00

      11/4/24 7:45:03 AM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on Zura Bio Limited with a new price target

      H.C. Wainwright initiated coverage of Zura Bio Limited with a rating of Neutral and set a new price target of $5.00

      9/5/24 8:35:06 AM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Piper Sandler initiated coverage on Zura Bio Limited with a new price target

      Piper Sandler initiated coverage of Zura Bio Limited with a rating of Overweight and set a new price target of $26.00

      5/3/24 7:45:08 AM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Zura Bio Limited

      SC 13G/A - Zura Bio Ltd (0001855644) (Subject)

      11/14/24 5:52:59 PM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Zura Bio Limited

      SC 13G/A - Zura Bio Ltd (0001855644) (Subject)

      11/14/24 5:06:21 PM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Zura Bio Limited

      SC 13G - Zura Bio Ltd (0001855644) (Subject)

      11/14/24 4:47:14 PM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Badial Verender S.

      4 - Zura Bio Ltd (0001855644) (Issuer)

      5/12/25 4:15:32 PM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Technology Officer Whale Gary

      4 - Zura Bio Ltd (0001855644) (Issuer)

      3/3/25 5:03:45 PM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Officer Nistala Kiran

      4 - Zura Bio Ltd (0001855644) (Issuer)

      3/3/25 5:02:54 PM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Zura Bio Limited filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Zura Bio Ltd (0001855644) (Filer)

      5/20/25 6:35:21 AM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Zura Bio Limited

      SCHEDULE 13G/A - Zura Bio Ltd (0001855644) (Subject)

      5/15/25 5:43:13 PM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13G filed by Zura Bio Limited

      SCHEDULE 13G - Zura Bio Ltd (0001855644) (Subject)

      5/14/25 4:11:09 PM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care